Kornimate/medical-research-clean huggingface dataset:
incremental velocity error as a new treatment in vestibular rehabilitation

Conditions: Mild Traumatic Brain Injury; Vestibular Neuropathy

Summary: the objective for this study is to compare outcome measures from vestibular rehabilitation (vpt) delivered in a traditional method against a new device incremental velocity error (ive) that improves physiologic performance of the vestibulo-ocular reflex. participants include active duty service members with mild traumatic brain injury (mtbi) and civilians with peripheral vestibular hypofunction. the investigators will use a clinical trial cross-over design with randomization to either the control (vpt) or experimental (ive) group and measure vestibulo-ocular reflex function as well as subjective and functional outcomes in order to investigate the best means to improve delivery of vestibular rehabilitation.


Eligibility criteria:
inclusion criteria: * greater than or equal to 18 years old * service members with mtbi and civilian patients with vestibular hypofunction, both of which reports vestibular symptoms (i.e. dizziness, imbalance). exclusion criteria: * any subjects with a self-reported history of significant ophthalmic, neuromuscular, cardiovascular (except hypertension), renal/electrolyte and psychiatric disorders * those with uncontrolled severe hypertension (systolic bp of \>200 mm hg and/or a diastolic bp of \> 110 mmhg at rest) * those with a recent history of alcohol and/or drug abuse within the past 6 months

Keywords: gaze stability balance vestibulo-ocular reflex (vor) gain dizzy
characterization of inclusion body myopathy associated with paget's disease of bone and frontotemporal dementia (ibmpfd)

Conditions: Inclusion Body Myopathy With Early-onset Paget Disease and Frontotemporal Dementia; Paget Disease of Bone; Frontotemporal Dementia; Myopathy

Summary: the investigators are researching families with inherited inclusion body myopathy (ibm) and/or paget disease of bone (pdb) and/or dementia (ftd) which is also called ibmpfd. ibmpfd is caused by mutations in the vcp gene. our main goal is to understand how changes in the vcp gene cause the muscle, bone and cognitive problems associated with the disease. the investigators are collecting biological specimen such as blood and urine samples, family and medical histories, questionnaire data of patients with a personal or family history of vcp associated disease. participants do not need to have all symptoms listed above in order to qualify. a select group of participants may be invited to travel to university of california, irvine for a two day program of local procedures such as an mri and bone scan. samples are coded to maintain confidentiality. travel is not necessary except for families invited for additional testing.


Eligibility criteria:
inclusion criteria: * inclusion criteria include all individuals with a combination of medical problems including muscle and bone disease and their family members. because historically vcp related muscle disease has been erroneously diagnosed with the following diagnoses, therefore if these patients also have a personal or family history of bone disease they will be considered eligible for the study: muscle disorders considered include: * limb girdle muscular dystrophy * myopathy * inclusion body myopathy * fsh (facioscapular muscular dystrophy) without the mutation * scapuloperoneal muscular dystrophy * amyotrophic lateral sclerosis * non specific muscular dystrophy and * bone disorders including: * paget disease of bone * fibrous dysplasia * diaphyseal medullary stenosis with malignant fibrous histiocytoma (dms-mfh) * non-specific bone disease eligible participants must also be: * subjects must to 18 years or older * subjects must to able to give consent * adult family members or spouses over the age of 18 of the affected individuals exclusion criteria: * under the age of 18. individuals who report a different unrelated diagnosis will be excluded from the study. testing to confirm different diagnoses will not be performed, instead patient will be questioned for this information and records will be obtained for confirmation of appropriate testing. those who are unable to provide consent for themselves will be excluded from participating in the study.

Keywords: ibmpfd - inclusion body myopathy associated with paget's disease of bone and frontotemporal dementia vcp gene - valosin-containing protein gene
etiology, clinical picture, complications and outcomes of necrotizing pancreatitis in children.

Conditions: Pancreatitis; Pancreatitis, Acute Necrotizing; Children

Summary: the aim of this research is to study the etiology, the clinical picture, the management, the complications and the outcomes of necrotic pancreatitis in children. currently, there is a significant number of errors in the early diagnosis of ap in children associated with the complexity of differential diagnosis, which leads to the untimely verification of the correct diagnosis and, consequently, to incorrect treatment tactics, which could be accompanied by an increase in the severe forms of the disease and an increase in mortality.

acute pancreatitis (ap) is an acute inflammatory disease of the exocrine pancreas. clinical manifestations vary from mild abdominal discomfort to metabolic disorders, sepsis, fluid sequestration, multiple organ failure and death. according to the international data, the annual incidence of ap in children is 3-13 cases per 100,000 people, but in recent years, there has been an increase in the incidence of this pathology. necrotic pancreatitis in children accounts for up to 25-30% of the cases of all forms of ap. despite the successes achieved in the diagnosis and treatment of ap, the mortality rate for this pathology is up to 5%, according to various authors. in addition, given the varying degrees of the prevalence of the destructive process in the pancreas and the parapancreatic tissue, the choice of surgical treatment still remains a subject of discussion. the treatment of moderately severe (msap) and severe (sap) necrotic pancreatitis is a complex task due to the variety of causes of the disease, the incompletely understood pathogenesis and the uncertainty in predicting the results. paralytic ileus with the development of intestinal failure is the main pathogenetic factor in the development of a septic condition in ap, but there is tendency of insufficient attention being paid to this fact in pediatric practice, which determines the lack of a unified approach to the treatment of intestinal failure syndrome.

Eligibility criteria:
inclusion criteria: * consent of the patient or legal representative * age from 0-18 years * moderate severe (msap) or severe acute pancreatitis (sap) according to atlanta criteria revisited in 2012 * acute pancreatitis was established in the presence of at least two of three criteria according to the classification developed by the insppire group (international study group of pediatric pancreatitis: in search for a cure): abdominal pain corresponding to the diagnostic hypothesis; an increase in amylase and / or lipase in the blood serum by ≥3 times; imaging findings characteristic of ap: abdominal ultrasound and/or contrast-enhanced ct. exclusion criteria: * mild acute pancreatitis * chronic pancreatitis * no consent from patient or legal representative

Keywords: pancreatitis acute necrotizing pancreatitis children
the effect of kinesio taping on ankle proprioception

Conditions: Sprains and Strains

Summary: this study examines the effect of kinesiology tape on proprioception and postural control in subjects with sub-acute and chronic ankle sprains/strain.

the a priori hypothesis of this study is that proprioception (knee repositioning error) and balance (sway velocity and center of pressure) will improve significantly after intervention (kinesiotape) in participants with a history of acute or chronic ankle sprains/strains.

Eligibility criteria:
inclusion criteria: * logan student, staff, or faculty * between the ages of 20 and 65 * previous history of ankle instability/sprains * a score of 6 out of 10 questions answered yes on the functional ankle instability form will qualify the candidate
effect of artemisinin-based combination therapies on schistosomiasis on malaria co-infection

Conditions: Schistosomiasis Haematobia

Summary: open labelled, non randomized study to evaluate the effects of artemisinin based combined therapies(acts) on schistosomiasis since praziquantel (pzq) which is presently the drug of choice for treating schistosomiasis (sts), is ineffective on immature stages and there is known parasite resistance. acts when combined with pzq, targeting different stages of the life cycle has shown some effectivity.

study population included all subjects in study area who signed a written informed consent form diagnosed with malaria- sts co-infection. those excluded were treated with pzq prior 6 weeks, have drug intolerance or pregnant. at inclusion, basic demographic data was recorded and urine samples analysed. during the follow up visits, urine samples were collected on d28 and d42 (6 weeks post treatment). post treatment assessment was done on urine samples collected on at least two consecutive days and at the end of follow up, all subjects were treated with a single dose pf pzq (40 mg/kg) as recommended by who.

Eligibility criteria:
inclusion criteria: * malaria infection diagnosed by rapid diagnostic tests (rdts) or thick blood smear * urinary schistosomiasis diagnosed by presence of schistosoma haematobium eggs in the urine before malaria treatment * written informed consent exclusion criteria: * patients treated with pzq during the previous 6 weeks * known intolerance /allergy to any study drug * pregnancy
diffusion-weighted cerebral mri and intra uterine growth restriction.

Conditions: Pregnant Women With Foetuses Presenting With Intra-uterine Growth Restriction

Summary: the purpose of this study is to compare the apparent diffusion coefficient in the frontal lobe of foetuses with intra-uterine growth restriction and poor neonatal outcome compared with foetuses with intra-uterine growth restriction and a good neonatal outcome.

intra-uterine growth restriction is associated with an increased risk of perinatal morbimortality. the objective of foetal monitoring is to assess foetal growth, foetal well-being and to evaluate ability to adapt to chronic hypoxia. the primary objective in antenatal care is to ischemic cerebral lesions. however, there is currently no relevant prenatal exam predictive for the risk of such lesions. foetal cerebral mri could highlight changes in apparent diffusion coefficient (adc) in some frontal cerebral territories in foetuses with intra-uterine growth restriction and poor neonatal outcome. these changes could be associated with a transient cerebral ischemia. the study of adc could be a useful tool in the prognostic evaluation of these foetuses.

Eligibility criteria:
inclusion criteria: * single pregnancy * estimated foetal weight ≤ 5th percentile * agreeing to participate * women age ≥ 18 years of age, speaking and understanding french language * covered by the french social security system exclusion criteria: * foetal malformation or foetal karyotype abnormal * infectious foetopathy * multiple pregnancy * refusal to participate * pregnant women aged \< 18 years old * pregnant women not understanding or speaking french language * not covered by french social security * contraindication to mri

Keywords: intra-uterine growth restriction mri apparent diffusion coefficient
dialysis symptom control-restless legs syndrome trial

Conditions: End Stage Renal Disease; Restless Legs Syndrome

Summary: the disco-rls trial is a randomized controlled trial to determine the safety and efficacy of pharmacologic therapy (ropinirole versus placebo and gabapentin versus placebo) for the treatment of restless legs syndrome in patients with end stage renal disease requiring hemodialysis.

the disco-rls trial is a randomized controlled trial to determine whether or not a fixed, low-dose therapy with ropinirole and/or gabapentin is safe and effective compared to either alone or placebo for the treatment of restless legs syndrome in patients with end stage renal disease receiving hemodialysis. disco-rls will randomize a total of 80 participants. participants will be randomized to 1 of 8 treatment sequences. each sequence is composed of 4 periods and in each period participants will receive 1 of 4 possible combinations of study medications (gabapentin+ropinirole, gabapentin+placebo ropinirole, ropinirole+placebo gabapentin, placebo gabapentin+placebo ropinirole). eligible participants will complete a 1-week run-in period followed by 4 periods of 4 weeks each for a total of 16-week follow-up after randomization. a final study visit will be completed at the end of the 16 week follow-up.

Eligibility criteria:
inclusion criteria: * age greater or equal to 18 years * has received at least 90 days of in-center hemodialysis at a frequency at least 3 times weekly * rls defined by 2012 revised international restless legs syndrome study group (irlssg) diagnostic criteria for rls and of moderate severity defined by an irls score greater or equal to 10 with symptoms more than 2 days per week (see irls question #7) * provides informed consent exclusion criteria: * hemoglobin\<80g/l in the previous 4 weeks * intolerance to a dopamine agonists (e.g. pramipexole or ropinirole) or alpha 2 delta ligands (e.g. gabapentin, neurontin, pregabalin, or lyrica) * change in medication to treat rls in previous 4 weeks * current pregnancy * planned kidney transplantation, travel or relocation in the next 6 months * unable to complete rls symptom and hrqol measurements due to language barrier or cognitive impairment
safety and efficacy study of ra101495 in subjects with generalized myasthenia gravis

Conditions: Generalized Myasthenia Gravis

Summary: the purpose of the study is to evaluate the safety and efficacy of ra101495 in patients with generalized myasthenia gravis (gmg). subjects will be randomized in a 1:1:1 ratio to receive daily sc doses of 0.1 mg/kg ra101495, 0.3 mg/kg ra101495, or matching placebo for 12 weeks.


Eligibility criteria:
inclusion criteria: * diagnosis of gmg \[myasthenia gravis foundation of america (mgfa) class ii-iva\] at screening * positive serology for acetylcholine receptor (achr) autoantibodies * qmg score ≥ 12 at screening and randomization * no change in corticosteroid dose for at least 30 days prior to randomization or anticipated to occur during the 12-week treatment period * no change in immunosuppressive therapy, including dose, for at least 30 days prior to randomization or anticipated to occur during the 12-week treatment period exclusion criteria: * thymectomy within 6 months prior to randomization or scheduled to occur during the 12 week treatment period * history of meningococcal disease * current or recent systemic infection within 2 weeks prior to randomization or infection requiring intravenous (iv) antibiotics within 4 weeks prior to randomization
targeted busulfan, fludarabine conditioning regimen for hematopoietic stem cell transplantation in grd

Conditions: Genetic Rare Disease

Summary: to evaluate the outcome of hematopoietic stem cell transplantation using targeted busulfan, fludarabine conditioning regimen in genetic rare disease

busulfan is a highly toxic drug with narrow therapeutic window used for the conditioning of hematopoietic stem cell transplantation. high exposure is associated with systemic toxicity such as veno-occlusive disease (vod) and underexposure is associated with graft failure or relapse. in this study the investigators plan to improve the outcome of hematopoietic stem cell transplantation by using optimal busulfan dose through pharmacokinetic study.

Eligibility criteria:
inclusion criteria: 1. patients who are diagnosed as genetic rare disease. 2. patients who need hematopoietic stem cell transplantation 3. age: up to 21 years 4. performance status: ecog 0-2. 5. patients must be free of significant functional deficits in major organs, but the following eligibility criteria may be modified in individual cases. 1. heart: a shortening fraction \> 30% and ejection fraction \> 45%. 2. liver: total bilirubin \ 60 ml/min/1.73m2. 6. patients must lack any active viral infections or active fungal infection. 7. appropriate donor is available: matched in 6/6 of a, b, dr loci. 8. patients (or one of parents if patients age \< 19) should sign informed consent. exclusion criteria: 1. pregnant or nursing women. 2. malignant or nonmalignant illness that is uncontrolled or whose control may be jeopardized by complications of study therapy. 3. psychiatric disorder that would preclude compliance.

Keywords: hematopoietic stem cell transplantation
a study to evaluate disease control, treatment patterns, burden of disease and quality of life in participants with moderate to severe inflammatory bowel disease (ibd)

Conditions: Crohn Disease; Colitis, Ulcerative; Inflammatory Bowel Disease

Summary: the purpose of this study is to evaluate the percentage of moderate to severe ibd participants with active disease at day 1.

this is a retrospective, cross-sectional, and non-interventional study of participants with ibd. the study will have a cross-sectional evaluation on day 1 to provide the real-world data of disease activity, treatment patterns, burden of disease and quality of life in participants with moderate to severe cd or uc. the study will involve an additional retrospective review of medical charts of participants of previous 3 years to describe the ibd treatments and use of other healthcare resources related with management of ibd. the study will enroll approximately 246 participants. all participants will be enrolled in one observational cohort. this multi-center trial will be conducted in argentina. the overall time for data collection in the study will be approximately 3 years before the start of the study (day 1).

Eligibility criteria:
inclusion criteria: 1. diagnosis of moderate to severe cd or uc for at least 6 months prior to day 1 appointment based on clinical or endoscopic or image criteria. exclusion criteria: 1. indeterminate or not classified colitis. 2. presenting mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation.

Keywords: drug therapy
benadamustine, fludarabine and busulfan conditioning in recipients of haploidentical stem cell transplantation (flubube)

Conditions: Leukemia, Acute Lymphoblastic; Myeloid Leukemia, Acute; Biphenotypic Acute Leukemia; Lymphoblastic Lymphoma; Myelodysplastic Syndromes; Myeloproliferative Neoplasm

Summary: haploidentical hematopoietic stem cell transplantation irrespective of the conditioning and graft-versus-host disease prophylaxis is associated with high frequency of primary and secondary graft failure. different technologies of with replete or depleted graft are associated with 10-20% of graft failures. fludarabine and busulfan conditioning is the most commonly used approach for a variety of disease. furthermore combination of fludarabine and bendamustine was sufficient to facilitate engraftment in patients with chronic lymphocytic leukemia and lymphomas. the aim of the study is to evaluate whether addition of bendamustine to fladarabine and busulfan conditioning reduces the risk of primary graft failure after haploidentical allograft.


Eligibility criteria:
inclusion criteria: * patients must have an indication for allogeneic hematopoietic stem cell transplantation with myeloablative conditioning for malignant disease * patients with 5-9/10 hla-matched related donor available. the donor and recipient must be identical by the following genetic loci: hla-a, hla-b, hla-cw, hla-drb1, and hla-dqb1. * peripheral blood stem cells or bone marrow as a graft source * no second malignancies requiring treatment * no severe concurrent illness exclusion criteria: * titer of anti-hla antibodies ≥ 5000 at the time of inclusion * moderate or severe cardiac dysfunction, left ventricular ejection fraction \<50% * moderate or severe decrease in pulmonary function, fev1 \<70% or dlco\<70% of predicted * respiratory distress \>grade i * severe organ dysfunction: ast or alt \>5 upper normal limits, bilirubin \>1.5 upper normal limits, creatinine \>2 upper normal limits * creatinine clearance \< 60 ml/min * uncontrolled bacterial or fungal infection at the time of enrollment * requirement for vasopressor support at the time of enrollment * karnofsky index \<30% * pregnancy * somatic or psychiatric disorder making the patient unable to sign informed consent

Keywords: fludarabine bendamustine busulfan myeloablative agonists hematopoietic stem cell transplantation allogeneic antineoplastic agents, alkylating
citrulline and arginase activity in severe sepsis and septic shock

Conditions: Intensive Care Units; Infection; Biomarkers; Sepsis; Septic Shock

Summary: sepsis is an acute pathology defined as an inappropriate response of the host to infection, resulting in the onset of organ failure (quick sofa ≥2, or sofa ≥2). septic shock is a sepsis associated with an elevation of lactate ≥ 2 mmol / l and an arterial hypotension requiring vasoactive drugs. several studies highlighted that sepsis is associated with a plasma l-arginine deficiency. this deficiency induces a lower availability of l-arginine for multiple metabolic pathways including those involved in the synthesis of nitric oxide (no) in the vascular endothelium via no synthase. no is the main endogenous vasodilator mediator, a lower synthesis induces a vascular and endothelial dysfunction that can promote the occurrence of an organic dysfunction during sepsis. decrease in available no was confirmed in patients with sepsis and appears correlated with severity. l-arginine deficiency can have multiple origins: * l-arginine deficiency resulting from a decrease in endogenous production from citrulline synthesized by the enterocytes. such enterocyte dysfunction has been confirmed in patients with sepsis and is characterized biologically by elevated plasma levels of i-fabp (intestinal fatty acid binding protein - enterocyte-specific protein, cytolysis marker) and lower than that of citrulline (hypocitrullinemia, marker of lower activity). * l-arginine deficiency may also result from a catabolism increase via arginase activity increased. this ubiquitous enzyme, having 2 isoforms (arg1 and arg2), allows the synthesis of urea and ornithine from l-arginine. an increase in arginase activity would decrease the available reserves of l-arginine for no synthesis. the objectives of this work is to evaluate, in patients with severe sepsis or septic shock, the prognostic value of the plasma arginase activity and the plasma expression of 2 isoforms arg1 and arg2, their kinetics, and the link between activity / expression of arginase and enterocyte dysfunction.


Eligibility criteria:
inclusion criteria: * 18 years old or older * patient admitted to icu * diagnosis, suspected or confirmed, of severe sepsis or septic shock * expected icu stay of at least 2 days * affiliation to a social security system or recipient of a such system * signed informed consent exclusion criteria: * pregnancy * chronic intestinal pathology * chronic renal failure defined by creatinine clearance \<50 ml / min / 1.73m2 (ckd-epi) * severe hepatic insufficiency (child-pugh stage c score) * legal incapacity or limited legal capacity * subject unlikely to cooperate with the study and / or weak cooperation anticipated by the investigator * patient within the exclusion period of another study or planned by the "national file of volunteers"

Keywords: icu, sepsis, septic shok, arginase, citrulline